| scholarly article | Q13442814 |
| P50 | author | Mark Pepys | Q6769213 |
| P2093 | author name string | Taylor KM | |
| Herbert J | |||
| Krausz T | |||
| Hutchinson WL | |||
| Sohail M | |||
| Griselli M | |||
| P2860 | cites work | An improved method for the isolation from Naja naja venom of cobra factor (CoF) free of phospholipase A | Q67019594 |
| Studies in vivo of cobra factor and murine C3 | Q67507672 | ||
| Serum amyloid P component in chronic renal failure and dialysis | Q67833572 | ||
| Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury | Q67969208 | ||
| Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis | Q68856319 | ||
| Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingom | Q70046050 | ||
| Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice | Q70289906 | ||
| C-reactive protein as a predictor of cardiac rupture after acute myocardial infarction | Q71043588 | ||
| Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment | Q71703487 | ||
| C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction | Q71971756 | ||
| C-reactive protein fifty years on | Q72458568 | ||
| C-reactive protein and complement in myocardial infarction and postinfarction heart failure | Q73948843 | ||
| C-reactive protein in postinfarction heart rupture | Q77295639 | ||
| The physiological structure of human C-reactive protein and its complex with phosphocholine | Q27618638 | ||
| Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium | Q28568260 | ||
| Isolation and characterization of C-reactive protein and serum amyloid P component in the rat | Q28582755 | ||
| Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli | Q28610085 | ||
| Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease | Q33895058 | ||
| Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction | Q34055000 | ||
| Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction | Q34056876 | ||
| A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells | Q34064320 | ||
| C-reactive protein reacts with the U1 small nuclear ribonucleoprotein | Q34417493 | ||
| Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis | Q35817146 | ||
| Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain | Q36231217 | ||
| The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats | Q36270882 | ||
| Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera | Q36273294 | ||
| C-reactive protein is protective against Streptococcus pneumoniae infection in mice | Q36345931 | ||
| Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein | Q36400340 | ||
| Complement localization and mediation of ischemic injury in baboon myocardium | Q37024840 | ||
| Long-Term Preservation of Ischemic Myocardium after Experimental Coronary Artery Occlusion | Q37051420 | ||
| Reduction by Cobra Venom Factor of Myocardial Necrosis after Coronary Artery Occlusion | Q37051852 | ||
| Inflammation in the course of early myocardial ischemia | Q37238694 | ||
| Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. | Q40162114 | ||
| Studies of acute-phase protein. II. Localization of Cx-reactive protein in heart in induced myocardial infarction in rabbits | Q40310047 | ||
| Complement activation by C-reactive protein complexes | Q40333589 | ||
| Phylogenetic aspects of C-reactive protein and related proteins | Q40333638 | ||
| Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component | Q41392379 | ||
| Complement inhibitors in myocardial ischemia/reperfusion injury | Q41707687 | ||
| Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. | Q46448164 | ||
| Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity | Q56595317 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| P304 | page(s) | 1733-1740 | |
| P577 | publication date | 1999-12-01 | |
| P1433 | published in | Journal of Experimental Medicine | Q3186912 |
| P1476 | title | C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction | |
| P478 | volume | 190 |
| Q38993371 | A conformational change of C-reactive protein in burn wounds unmasks its proinflammatory properties |
| Q58466353 | A novel haplotype within C-reactive protein gene influences CRP levels and coronary heart disease risk in Northwest Indians |
| Q35498749 | A quantitative lateral flow assay to detect complement activation in blood |
| Q45221683 | Activated human PMN synthesize and release a strongly fucosylated glycoform of alpha1-acid glycoprotein, which is transiently deposited in human myocardial infarction |
| Q37964203 | Acute phase proteins in animals |
| Q37961185 | Acute-phase response in chronic urticaria |
| Q34605296 | Alterations of the classic pathway of complement in adipose tissue of obesity and insulin resistance |
| Q48876259 | Amyloid plaques dissociate pentameric to monomeric C-reactive protein: a novel pathomechanism driving cortical inflammation in Alzheimer's disease? |
| Q35139924 | Analytical performance of a highly sensitive C-reactive protein-based immunoassay and the effects of laboratory variables on levels of protein in blood |
| Q36649671 | Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade |
| Q33607563 | Animal models of C-reactive protein |
| Q37307880 | Anticomplement therapy. |
| Q37599596 | Association between endogenous complement inhibitor and myocardial salvage in patients with myocardial infarction |
| Q82297937 | Association between serum C-reactive protein elevation and atrial fibrillation after first anterior myocardial infarction |
| Q43002262 | Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein |
| Q90441319 | C-Reactive Protein and Its Structural Isoforms: An Evolutionary Conserved Marker and Central Player in Inflammatory Diseases and Beyond |
| Q24675774 | C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity |
| Q42176471 | C-reactive protein activates complement in infarcted human myocardium |
| Q35562701 | C-reactive protein and cardiovascular disease: new insights from an old molecule |
| Q36562274 | C-reactive protein and cardiovascular disease: weighing the evidence |
| Q38078307 | C-reactive protein and the biology of disease |
| Q73127397 | C-reactive protein and the risk of cardiovascular mortality |
| Q42332242 | C-reactive protein as a pro-inflammatory mediator in cardiovascular disease by its ability to activate complement: additional proof and hypothetical mechanisms |
| Q37754545 | C-reactive protein at the interface between innate immunity and inflammation |
| Q80424467 | C-reactive protein augments hypoxia-induced apoptosis through mitochondrion-dependent pathway in cardiac myocytes |
| Q37428732 | C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death |
| Q37777888 | C-reactive protein is a mediator of cardiovascular disease |
| Q41549723 | C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty |
| Q46134722 | C-reactive protein modulates human lung fibroblast migration |
| Q37114370 | C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo |
| Q28573623 | C-reactive protein triggers inflammatory responses partly via TLR4/IRF3/NF-κB signaling pathway in rat vascular smooth muscle cells |
| Q47191457 | C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction |
| Q38493334 | C-reactive protein, lipoprotein(a), homocysteine, and male sex contribute to carotid atherosclerosis in peritoneal dialysis patients |
| Q24672855 | C-reactive protein: a critical update |
| Q35942423 | C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity |
| Q28194885 | C-reactive protein: the pawn has been promoted to queen |
| Q40395198 | CRP velocity and short-term mortality in ST segment elevation myocardial infarction |
| Q34257488 | CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction? |
| Q35747543 | Cardiomyopathy is linked to complement activation |
| Q37815130 | Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues |
| Q34241121 | Chronic rejection |
| Q39314024 | Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. |
| Q41194503 | Combination stem cell therapy for heart failure |
| Q42928117 | Comparison of C-reactive protein and albumin excretion as prognostic markers for 10-year mortality after myocardial infarction. |
| Q40647004 | Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris |
| Q34083722 | Complement activation in heart diseases. Role of oxidants |
| Q37769810 | Complement and periodontitis. |
| Q54377887 | Complement factor concentrations in patients with acute myocardial infarction: time course and ability to predict left ventricular dysfunction. |
| Q36376363 | Continual low-level activation of the classical complement pathway |
| Q35953555 | Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus? |
| Q35045446 | Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart |
| Q51520259 | Dietary astaxanthin enhances immune response in dogs. |
| Q55303250 | Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation: Evidence for a Direct Biological Role of C-Reactive Protein and Its Conformational Changes. |
| Q74419354 | Effects of C-reactive protein and pentosan polysulphate on human complement activation |
| Q35026389 | Effects of an antisense oligonucleotide inhibitor of C-reactive protein synthesis on the endotoxin challenge response in healthy human male volunteers |
| Q44877647 | Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation |
| Q45341410 | Efferocytosis and Outside-In Signaling by Cardiac Phagocytes. Links to Repair, Cellular Programming, and Intercellular Crosstalk in Heart |
| Q61928027 | Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality |
| Q37907327 | Established and novel biomarkers in ST-elevation myocardial infarction |
| Q46851818 | Estrogen replacement raises rat CRP without evidence of complement activation |
| Q37004632 | Evaluating the role of biomarkers for cardiovascular risk prediction: focus on CRP, BNP and urinary microalbumin |
| Q36329753 | Evaluation of systemic markers of inflammation in atomic-bomb survivors with special reference to radiation and age effects |
| Q27021449 | Fcγ receptors and ligands and cardiovascular disease |
| Q42594950 | Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels--a study in twins |
| Q33530136 | Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke |
| Q42767535 | Heart disease and the inflammatory response |
| Q34963775 | Heme interacts with c1q and inhibits the classical complement pathway |
| Q51124625 | High-sensitivity C-reactive protein as a novel marker in early diagnosis of ovarian torsion: an experimental study. |
| Q77924171 | Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis |
| Q36113661 | Human C-reactive protein accentuates macrophage activity in biobreeding diabetic rats |
| Q24338918 | Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis |
| Q34021492 | Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. |
| Q48276541 | Human C-reactive protein enhances vulnerability of immature rats to hypoxic-ischemic brain damage: a preliminary study |
| Q47400800 | Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats |
| Q37327619 | Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo |
| Q36558323 | Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats |
| Q35588500 | IgM colocalises with complement and C reactive protein in infarcted human myocardium |
| Q41716490 | Immunohistochemical expression of inflammatory markers in sudden infant death; ancillary tests for identification of infection |
| Q85049501 | Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction |
| Q40503940 | Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study |
| Q44518799 | Inflammation, thrombosis and atherosclerosis: results of the Glostrup study. |
| Q35933310 | Inflammatory gene polymorphisms and risk of postoperative myocardial infarction after cardiac surgery |
| Q47981043 | Inflammatory responses after percutaneous coronary intervention in patients with acute myocardial infarction or stable angina pectoris |
| Q28577389 | Inhibition of classical complement activation attenuates liver ischaemia and reperfusion injury in a rat model |
| Q34241109 | Innate immune responses to transplants: a significant variable with cadaver donors |
| Q36014039 | Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials |
| Q37283121 | Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation |
| Q37821238 | Ischemia/reperfusion injury: The role of immune cells |
| Q58033509 | Lack of Association Between Genetic Variation in 9 Innate Immunity Genes and Baseline CRP Levels |
| Q36070412 | Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis |
| Q27318134 | Local inflammation induces complement crosstalk which amplifies the antimicrobial response |
| Q58314403 | Markers of the Acute Phase Response in Cardiovascular Disease: An Update |
| Q98771706 | Mediastinal Lymphadenopathy, Class-Switched Auto-Antibodies and Myocardial Immune-Complexes During Heart Failure in Rodents and Humans |
| Q43702621 | Myeloperoxidase influences the complement regulatory function of modified C-reactive protein |
| Q28192292 | Opportunities for the treatment of inflammation in cardiovascular disease |
| Q34188034 | Oxidized phosphatidylcholines: pattern recognition ligands for multiple pathways of the innate immune response |
| Q30315815 | Pathophysiology of Heart Failure |
| Q27687176 | Pentraxins (CRP, SAP) in the process of complement activation and clearance of apoptotic bodies through Fcγ receptors |
| Q28676262 | Pentraxins: structure, function, and role in inflammation |
| Q48664598 | Plasma C-reactive protein predicts left ventricular remodeling and function after a first acute anterior wall myocardial infarction treated with coronary angioplasty: comparison with brain natriuretic peptide. |
| Q80205931 | Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol |
| Q52980725 | Prediction of Infarct Transmurality From C-Reactive Protein Level and Mean Platelet Volume in Patients With ST-Elevation Myocardial Infarction: Comparison of the Predictive Values of Cardiac Enzymes. |
| Q85209593 | Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial |
| Q36925542 | Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases |
| Q90218083 | Prognostic Impact of Pre- and Post-operative P-CRP Levels in Pancreatic Cancer Patients |
| Q34446461 | Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself |
| Q37531490 | Proteomic analysis of aneurysm healing mechanism after coil embolization: comparison of dense packing with loose packing |
| Q28581087 | Rat C-reactive protein activates the autologous complement system |
| Q38221846 | Recognition functions of pentameric C-reactive protein in cardiovascular disease |
| Q35787045 | Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. |
| Q50319143 | Refractory chronic spontaneous urticaria and permanent atrial fibrillation associated with dental infection: Mere coincidence or something more to it? |
| Q26825806 | Repair after myocardial infarction, between fantasy and reality: the role of chemokines |
| Q44770173 | Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan |
| Q42616194 | Salivary constituents and acidogenic microbial counts in coronary artery bypass graft patients from baseline to three-years after operation |
| Q56966139 | Selective apheresis of C-reactive protein: a new therapeutic option in myocardial infarction? |
| Q35077911 | Sensitive markers of inflammation make it possible to study the chronic process: the rise of interest in low levels of C-reactive protein |
| Q44416999 | Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction--role of neurohormones and cytokines |
| Q40144630 | Serum level of C-reactive protein is not a parameter to determine the difference between viral and atypical bacterial infections |
| Q36783729 | Should C-reactive protein be a target of therapy? |
| Q52576446 | Studies on the interactions between C-reactive protein and complement proteins. |
| Q34600051 | Sulodexide: a renewed interest in this glycosaminoglycan |
| Q26999377 | Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes |
| Q33995386 | Targeting C-reactive protein for the treatment of cardiovascular disease. |
| Q38119156 | Targeting urocortin signaling pathways to enhance cardioprotection: is it time to move from bench to bedside? |
| Q37316791 | The Impact of Ischemic Time on the Predictive Value of High-Sensitivity C-Reactive Protein in ST-Segment Elevation Myocardial Infarction Patients Treated by Primary Percutaneous Coronary Intervention |
| Q59127894 | The Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs |
| Q37419567 | The adenosine A₂A receptor - myocardial protectant and coronary target in endotoxemia |
| Q44283232 | The canine mast cell activation via CRP. |
| Q36984472 | The classical complement pathway in transplantation: unanticipated protective effects of C1q and role in inductive antibody therapy |
| Q35153653 | The complement system as a therapeutic target in autoimmunity |
| Q34412336 | The complement system: history, pathways, cascade and inhibitors |
| Q35999439 | The connection between C-reactive protein and atherosclerosis |
| Q47772976 | The effect of C-reactive protein deposition on myocardium with ischaemia-reperfusion injury in rats |
| Q36253316 | The effect of C1 inhibitor on myocardial ischemia and reperfusion injury |
| Q37144130 | The evolving role of C-reactive protein in atherothrombosis |
| Q46601818 | The functional role of C-reactive protein in aortic wall calcification |
| Q37096652 | The immune system and cardiac repair. |
| Q42770077 | The renaissance of C reactive protein |
| Q28193154 | The role of inflammation and infection in the pathogenesis and evolution of coronary artery disease |
| Q37357462 | The role of innate immunity in atherogenesis |
| Q37604483 | Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites |
| Q35231861 | Understanding postprandial inflammation and its relationship to lifestyle behaviour and metabolic diseases |
| Q47626900 | Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases |
| Q36031419 | Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction |
| Q36225152 | Value of C-reactive protein in predicting left ventricular remodelling in patients with a first ST-segment elevation myocardial infarction |
| Q38149507 | Vein graft failure |
Search more.